Discovery of Novel, Highly Potent, and Selective Quinazoline-2-carboxamide-Based Matrix Metalloproteinase (MMP)-13 Inhibitors without a Zinc Binding Group Using a Structure-Based Design Approach-Reference-Cited by-同舟云学术

Discovery of Novel, Highly Potent, and Selective Quinazoline-2-carboxamide-Based Matrix Metalloproteinase (MMP)-13 Inhibitors without a Zinc Binding Group Using a Structure-Based Design Approach

Published:2014-10-15 Issue:21 Volume:57 Page:8886-8902
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Nara Hiroshi¹,Sato Kenjiro¹,Naito Takako¹,Mototani Hideyuki¹,Oki Hideyuki¹,Yamamoto Yoshio¹,Kuno Haruhiko¹,Santou Takashi¹,Kanzaki Naoyuki¹,Terauchi Jun¹,Uchikawa Osamu¹,Kori Masakuni¹

Affiliation:

1. Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm500981k

Reference34 articles.

1. Coxibs and Cardiovascular Disease

2. Biochemical Characterization of Human Collagenase-3

3. Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage.